DaltonTx raises £4 million seed financing to build the intelligence backbone of drug discovery
DaltonTx, a UK-based technology company, today announces its exit from from stealth and the completion of a £4 million seed financing round to build adaptive, AI-enabled discovery platforms that reshape the economics, timelines, and outcomes of R&D so breakthrough medicines reach patients faster.
AI offers pharma a unique opportunity to discover medicines more effectively and efficiently. However, building adaptive AI platforms requires years of investment in software engineering, coupled with deep understanding of the science and technology. DaltonTx solves this with a disease- and technology-agnostic adaptive platform that plugs directly into pharma, biotech, and CRO workflows, giving teams instant access to AI-enabled discovery instead of spending years developing these capabilities in-house.
